Lexicon Pharmaceuticals (NASDAQ:LXRX) Raised to Sell at StockNews.com

StockNews.com upgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) to a sell rating in a report released on Monday.

Separately, Needham & Company LLC reaffirmed a hold rating on shares of Lexicon Pharmaceuticals in a research note on Thursday, April 11th.

Lexicon Pharmaceuticals Price Performance

LXRX stock opened at $1.62 on Monday. The stock has a 50-day moving average price of $2.39 and a two-hundred day moving average price of $1.70. Lexicon Pharmaceuticals has a 1 year low of $0.92 and a 1 year high of $3.79. The stock has a market cap of $398.91 million, a PE ratio of -2.02 and a beta of 1.27. The company has a current ratio of 5.60, a quick ratio of 5.58 and a debt-to-equity ratio of 1.07.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.03. Lexicon Pharmaceuticals had a negative return on equity of 138.54% and a negative net margin of 14,573.20%. The company had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $0.68 million. Equities analysts forecast that Lexicon Pharmaceuticals will post -0.71 EPS for the current fiscal year.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

A number of large investors have recently modified their holdings of LXRX. Bank of Montreal Can bought a new stake in Lexicon Pharmaceuticals during the first quarter worth about $26,000. Kestra Advisory Services LLC acquired a new position in shares of Lexicon Pharmaceuticals during the 2nd quarter worth approximately $33,000. ExodusPoint Capital Management LP bought a new stake in shares of Lexicon Pharmaceuticals during the 1st quarter worth approximately $38,000. Cantor Fitzgerald L. P. acquired a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter valued at approximately $25,000. Finally, BNP Paribas Arbitrage SNC grew its stake in shares of Lexicon Pharmaceuticals by 125.1% in the first quarter. BNP Paribas Arbitrage SNC now owns 18,552 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 10,312 shares in the last quarter. 74.70% of the stock is currently owned by institutional investors and hedge funds.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.